- Home
- TGL vs SILO Comparison
TGL vs SILO Comparison
Compare TGL & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- SILO
- Stock Information
- Founded
- TGL 2020
- SILO 2010
- Country
- TGL United States
- SILO United States
- Employees
- TGL N/A
- SILO N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- SILO Apparel
- Sector
- TGL Technology
- SILO Consumer Discretionary
- Exchange
- TGL Nasdaq
- SILO Nasdaq
- Market Cap
- TGL 3.9M
- SILO 4.3M
- IPO Year
- TGL 2022
- SILO N/A
- Fundamental
- Price
- TGL $1.05
- SILO $0.64
- Analyst Decision
- TGL
- SILO
- Analyst Count
- TGL 0
- SILO 0
- Target Price
- TGL N/A
- SILO N/A
- AVG Volume (30 Days)
- TGL 2.9M
- SILO 2.2M
- Earning Date
- TGL 08-25-2025
- SILO 08-12-2025
- Dividend Yield
- TGL N/A
- SILO N/A
- EPS Growth
- TGL N/A
- SILO N/A
- EPS
- TGL N/A
- SILO N/A
- Revenue
- TGL $1,468,790.00
- SILO $72,102.00
- Revenue This Year
- TGL N/A
- SILO $1.86
- Revenue Next Year
- TGL N/A
- SILO N/A
- P/E Ratio
- TGL N/A
- SILO N/A
- Revenue Growth
- TGL N/A
- SILO N/A
- 52 Week Low
- TGL $1.01
- SILO $0.41
- 52 Week High
- TGL $147.00
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- TGL 32.05
- SILO 51.15
- Support Level
- TGL $1.02
- SILO $0.60
- Resistance Level
- TGL $1.11
- SILO $0.61
- Average True Range (ATR)
- TGL 0.10
- SILO 0.06
- MACD
- TGL 0.02
- SILO 0.02
- Stochastic Oscillator
- TGL 6.44
- SILO 43.36
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.